Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer.
about
Current efforts and future prospects in the development of live mycobacteria as vaccinesRedirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy.A case of disseminated Mycobacterium bovis 2 years post-intravesicular Bacillus Calmette-Guérin therapy for superficial urinary bladder cancer.The Oncopig Cancer Model as a Complementary Tool for Phenotypic Drug Discovery.
P2860
Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Recombinant Mycobacterium bovi ...... uscle invasive bladder cancer.
@en
type
label
Recombinant Mycobacterium bovi ...... uscle invasive bladder cancer.
@en
prefLabel
Recombinant Mycobacterium bovi ...... uscle invasive bladder cancer.
@en
P2093
P2860
P1476
Recombinant Mycobacterium bovi ...... uscle invasive bladder cancer.
@en
P2093
F K Seixas
K R Begnini
T Collares
P2860
P2888
P304
P356
10.1007/S00253-015-6495-3
P407
P577
2015-03-21T00:00:00Z
P5875
P6179
1021172445